Dr Christina Reith
BSc (Hons), MBChB (Hons), PhD, FRCP (Glasg.), FFPM
Senior Clinical Research Fellow
- Honorary Consultant Physician, Pharmaceutical Medicine, Oxford University Hospitals NHS Foundation Trust
Christina studied at The University of Glasgow, gaining a first class honours degree in medical biochemistry and subsequently her medical degree with honours.
Christina completed her MRCP whilst working in the NHS, and subsequently completed speciality training in Pharmaceutical Medicine in 2011. She became a Fellow of The Royal College of Physicians and Surgeons of Glasgow in 2012, and a Fellow of the Faculty of Pharmaceutical Medicine in 2013.
Since joining the Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU; now part of the Nuffield Department of Population Health) in 2004, Christina has mainly worked on large-scale clinical trials (such as the Study of Heart and Renal Protection [SHARP] in patients with moderate-to-severe chronic kidney disease, which recruited >9000 patients in nearly 400 hospitals in 18 countries) and individual participant data meta-analyses in relation to cardiovascular disease, such as those conducted by the Cholesterol Treatment Trialists’ (CTT) Collaboration, and the Antithrombotic Trialists’ (ATT) Collaboration. She has a particular research interest in the reliable assessment of drug safety using such large-scale randomized data.
Christina is also a keen proponent of streamlined clinical trial methodology, and is a Board Member for the Clinical Data Interchange Standards Consortium (CDISC) which aims to develop and advance high quality data standards.
She is actively involved in supervision and training, teaching on two MSc courses, being a GMC-approved Educational Supervisor for Pharmaceutical Medicine specialty training, and acting as a College Adviser for students at Green Templeton College.
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
RECOVERY Collaborative Group None., (2021), Lancet, 397, 605 - 612
A pragmatic tool for drug discovery.
Bobbitt DR. et al, (2020), Drug Discov Today
CV Care: Lipid-modifying Agents--From Statins to PCSK9 inhibitors
PREISS D. and REITH C., (2019), JACC - Journal of the American College of Cardiology
Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I. et al, (2019), Kidney Int, 96, 170 - 179
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials.
Cholesterol Treatment Trialists' Collaboration None., (2019), Lancet, 393, 407 - 415